KLRK1 and hematologic disorder: Besides, a phase I trial of autologous NKG2D CAR-T in patients with hematological malignancies revealed that NKG2D CAR-T cells have a good safety profile (9), indicating that NKG2DL is a potential target for CAR-T therapy.